Benznidazole-resistance in Trypanosoma cruzi: Evidence that distinct mechanisms can act in concert

Molecular and Biochemical Parasitology

Volumn 193, Issue 1, 2014, Pages 17-19

  Campos, Mônica C O ^a,b   Leon, Leonor L ^b   Taylor, Martin C ^a   Kelly, John M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Benznidazole; Drug resistance; Nitroreductase; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX; NITROREDUCTASE; ANTIPROTOZOAL AGENT; NITROIMIDAZOLE DERIVATIVE; STOP CODON;

ARTICLE; CHROMOSOME; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; MUTATION; NONHUMAN; PRIORITY JOURNAL; STOP CODON; TRYPANOSOMA CRUZI; AUTORADIOGRAPHY; CHAGAS DISEASE; CHROMOSOME STRUCTURE; DRUG MECHANISM; DRUG POTENCY; ELECTROPHORESIS; GENE CONVERSION; GENE MUTATION; KARYOTYPING; TREATMENT FAILURE; DRUG EFFECTS; DRUG SENSITIVITY; ENZYMOLOGY; GENE DELETION; GENETICS; METABOLISM;

TRYPANOSOMA CRUZI;

ANTIPROTOZOAL AGENTS; CODON, NONSENSE; DRUG RESISTANCE; GENE DELETION; NIFURTIMOX; NITROIMIDAZOLES; NITROREDUCTASES; PARASITIC SENSITIVITY TESTS; TRYPANOSOMA CRUZI;

EID: 84894243445     PISSN: 01666851     EISSN: 18729428     Source Type: Journal    
DOI: 10.1016/j.molbiopara.2014.01.002     Document Type: Article

References (16)

1. C. Bern, and S.P. Montgomery An estimate of the burden of Chagas disease in the United States Clin Infect Dis 49 2009 e52 e54
2. B.Y. Lee, K.M. Bacon, M.E. Bottazzi, and P.J. Hotez Global economic burden of Chagas disease: a computational simulation model Lancet Infect Dis 13 2013 342 348
3. S.R. Wilkinson, and J.M. Kelly Trypanocidal drugs: mechanisms, resistance and new targets Expert Rev Mol Med 11 31 2009 1 24
4. J.A. Castro, M.M. de Mecca, and L.C. Bartel Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis) Hum Exp Toxicol 25 2006 471 479
5. S.R. Wilkinson, M.C. Taylor, D. Horn, J.M. Kelly, and I. Cheeseman A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes Proc Natl Acad Sci U S A 105 2008 5022 5027
6. B.S. Hall, and S.R. Wilkinson Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation Antimicrob Agents Chemother 56 2012 115 123
7. B.S. Hall, C. Bot, and S.R. Wilkinson Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites J Biol Chem 286 2011 13088 13095
8. A.M. Mejia, B.S. Hall, M.C. Taylor, A. Gómez-Palacio, S.R. Wilkinson, and O. Triana-Chávez et al. Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population J Inf Dis 206 2012 220 228
9. S.M. Murta, R.T. Gazzinelli, Z. Brener, and A.J. Romanha Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox Mol Biochem Parasitol 93 1998 203 214
10. L.S. Filardi, and Z. Brener Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease Trans R Soc Trop Med Hyg 81 1987 75575 75579
11. M.C. Campos, D.B. Castro-Pinto, G.A. Ribeiro, M.M. Berredo-Pinho, L.H. Gomes, and M.S. da Silva Bellieny et al. P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance Parasitol Res 112 2013 2341 2351
12. S.O. Obado, M.C. Taylor, S.R. Wilkinson, E.V. Bromley, and J.M. Kelly Functional mapping of a trypanosome centromere by chromosome fragmentation identifies a 16 kb GC-rich transcriptional strand-switch domain as a major feature Genome Res 15 2005 36 43
13. R.T. Souza, F.M. Lima, R.M. Barros, D.R. Cortez, M.F. Santos, and E.M. Cordero et al. Genome size, karyotype polymorphism and chromosomal evolution in Trypanosoma cruzi PLoS ONE 6 2011 e23042
14. S. Alsford, S. Eckert, N. Baker, L. Glover, A. Sanchez-Flores, and K.F. Leung et al. High-throughput decoding of antitrypanosomal drug efficacy and resistance Nature 482 2012 232 236
15. G. Kendall, A.F. Wilderspin, F. Ashall, M.A. Miles, and J.M. Kelly Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase does not conform to the hotspot topogenic signal model EMBO J 9 1990 2751 2758
16. G.N. Parkinson, J.V. Skelly, and S. Neidle Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme J Med Chem 43 2000 3624 3631